Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.

Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Abstract Text:

Katri S Selander,David A Brown,Guillermo Blanco Sequeiros,Mark Hunter,Renee Desmond,Teija Parpala,Juha Risteli,Samuel N Breit,Arja Jukkola-Vuorinen,Katri S Selander,David A Brown,Guillermo Blanco Sequeiros,Mark Hunter,Renee Desmond,Teija Parpala,Juha Risteli,Samuel N Breit,Arja Jukkola-Vuorinen,

Macrophage-inhibitory cytokine-1 (MIC-1) is a divergent member of the transforming growth factor beta superfamily. It is up-regulated by nonsteroidal anti-inflammatory drugs and is highly expressed in human prostate cancer leading to high serum MIC-1 concentrations with advanced disease. A role for MIC-1 has been implicated in the process of early bone formation, suggesting that it may also mediate sclerosis at the site of prostate cancer bone metastases. Consequently, the aim of this study was to retrospectively determine the relationship of serum MIC-1 concentration and other markers related to current and future prostate cancer bone metastasis in a cohort of 159 patients with prostate cancer. Serum markers included cross-linked carboxy-terminal telopeptide of type I collagen, prostate-specific antigen, and amino-terminal propeptide of type I procollagen (PINP). The mean values of all the biomarkers studied were significantly higher in patients with baseline bone metastases (BM+, n = 35), when compared with those without bone metastases (BM-, n = 124). In a multivariate logistic model, both MIC-1 and PINP independently predicted the presence of baseline bone metastasis. Based on receiver operator curve analysis, the best predictor for the presence of baseline bone metastasis was MIC-1, which was significantly better than carboxy-terminal telopeptide of type I collagen, prostate-specific antigen, and PINP. Patients who experienced bone relapse had significantly higher levels of baseline MIC-1 compared with patients who did not (1476.7 versus 988.4; P = 0.03). Current use of acetylsalicylic acid did not influence serum MIC-1 levels in this cohort. Although requiring validation prospectively, these results suggest that serum MIC-1 determination may be a valuable tool for the diagnosis of current and future bone metastases in patients with prostate cancer.

Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Publishing Authors By Initials

KS Selander,DA Brown,GB Sequeiros,M Hunter,R Desmond,T Parpala,J Risteli,SN Breit,A Jukkola-Vuorinen,KS Selander,DA Brown,GB Sequeiros,M Hunter,R Desmond,T Parpala,J Risteli,SN Breit,A Jukkola-Vuorinen,

For similar biological factors: biological markers: tumor markers, biological research abstracts see: biological factors: biological markers: tumor markers, biological research

PUBMED ID PMID:

MEDLINE DATE:

Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Cancer epidemiology, biomarkers & prevention : a p

VOLUME: 16

Page Numbers: 532-7

Journal Abbreviation: Cancer Epidemiol. Biomarkers P

ISSN: 1055-9965

DAY: 3

MONTH: Mar

YEAR: 2007

Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9200608

Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Keywords Mesh Terms:

KEYWORDS: Tumor Markers, Biological

MESH TERMS: blood

Chemical & Substance for Abstract: Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Information

Substance Name: Prostate-Specific Antigen

Registry Number: EC 3.4.21.77

Grant and Affiliation Information for Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.

AFFILIATION: Department of Medicine, Division of Hematology-Oncology, University of Alabama at Birmingham, WTI T558, 1824 6th Avenue South, Birmingham, AL 35294-3300, USA. Katri.Selander@ccc.uab.edu

Country: United States

AGENCY: United States NIAMS

GRANT: 5P30 AR46031-05

ACRONYM: AR

MEDLINETA: Cancer Epidemiol Biomarkers Pr

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases Related Publications

• Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.